CT radiomics predicts survival in NSCLC patients
CT radiomics can be useful for predicting survival in patients receiving immunotherap...Read more on AuntMinnie.comRelated Reading: How higher radiation stacks up when treating lung cancer Radiomics, AI can guide NSCLC treatment decisions Radiomics can aid management of lung cancer patients PET shows promise for detecting NSCLC recurrence Radiomics can predict treatment outcome for NSCLC (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 16, 2021 Category: Radiology Source Type: news

Survival Benefit and Toxicity of Icotinib for EGFR+ NSCLC Survival Benefit and Toxicity of Icotinib for EGFR+ NSCLC
Might the use of adjuvant icotinib improve survival among EGFR mutation-positive NSCLC patients? What do we know about the treatment-related toxicities?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Immunotherapy alone extended life for metastatic lung cancer patients with KRAS mutation
(University of Pennsylvania School of Medicine) Real-word evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2021 Category: Cancer & Oncology Source Type: news

Presurgical Nivo/Chemo Boosts pCR Rates in NSCLC Presurgical Nivo/Chemo Boosts pCR Rates in NSCLC
For patients with resectable non –small cell lung cancer (NSCLC) tumors, adding immunotherapy to platinum-based chemotherapy improved pathologic complete response (pCR) rates.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 12, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Level of chromosomal abnormality in lung cancer may predict immunotherapy response
(Dana-Farber Cancer Institute) Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy - an abnormal number of chromosomes - tend to respond better to immune checkpoint inhibitor drugs than patients with higher levels, Dana-Farber Cancer Institute researchers will report at the virtual AACR Annual Meeting 2021. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2021 Category: Cancer & Oncology Source Type: news

FDA D.I.S.C.O. Burst Edition: Lorbrena (lorlatinib) for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive, detected by an FDA-approved test
Listen to a soundcast of the March 3, 2021 approval of Lorbrena (lorlatinib) for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive, detected by an FDA-approved test. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA D.I.S.C.O. Burst Edition: Libtayo (cemiplimab-rwlc) for first-line treatment of patients with advanced NSCLC (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression with no eGFR, anaplastic lymphoma kinase or receptor tyrosine kinase aberrations
Listen to a soundcast of the February 22nd 2021 FDA approval of Libtayo (cemiplimab-rwlc) for first-line treatment of patients with advanced NSCLC (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Tislelizumab Plus Chemo Slows Advanced Squamous NSCLC
Progression - free survival significantly longer with tislelizumab plus chemotherapy versus chemotherapy alone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 5, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Pulmonology, Journal, Source Type: news

Tislelizumab Plus Chemo Slows Advanced Squamous NSCLC
MONDAY, April 5, 2021 -- For patients with advanced squamous non-small cell lung cancer (sq- NSCLC), adding tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 5, 2021 Category: Pharmaceuticals Source Type: news

Radiomics AI algorithm differentiates sclerotic bone lesions
A radiomics-based machine-learning model can differentiate bone islands an...Read more on AuntMinnie.comRelated Reading: MRI radiomics can predict risk of breast cancer recurrence CCTA radiomics yields insights into nature of coronary artery disease AI, radiomics predicts prostate cancer recurrence Radiomics, AI can guide NSCLC treatment decisions CT radiomics classifies small nodules found in CT lung screening (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 1, 2021 Category: Radiology Source Type: news

Pembrolizumab monotherapy cost effective in metastatic non-squamous NSCLC with high PD-L1 expression in Switzerland
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2021 Category: Drugs & Pharmacology Source Type: news

Atezolizumab not cost effective for NSCLC with high PD-L1 expression
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2021 Category: Drugs & Pharmacology Source Type: news

RF ablation relieves pain for bone cancer patients in 3 days
Radiofrequency (RF) ablation provides pain relief to patients whose cancer ha...Read more on AuntMinnie.comRelated Reading: Outpatient radiology procedure offers arthritis relief DC docs use MR-HIFU to treat bone tumor RF ablation for elderly NSCLC patients offers cost benefits Interventional techniques improve outcomes in colorectal liver metastases (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 26, 2021 Category: Radiology Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Media News - March 26, 2021 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Investor Update - March 26, 2021 Category: Pharmaceuticals Source Type: news

Second drug targeting KRASG12C shows benefit in mutated non-small-cell lung cancer
(European Society for Medical Oncology) Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) harbouring this mutation, according to results from a study with the KRASG12C inhibitor adagrasib reported at the European Lung Cancer Virtual Congress 2021. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 25, 2021 Category: Cancer & Oncology Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news

FDA D.I.S.C.O. Burst Edition: Lorbrena (lorlatinib) for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive, detected by an FDA-approved test
Listen to a soundcast of the March 3, 2021 approval of Lorbrena (lorlatinib) for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive, detected by an FDA-approved test. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 19, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Akesis brain disease imaging system cleared
Radiation therapy developer Akesis announced it has received 510(k) clearanc...Read more on AuntMinnie.comRelated Reading: Akesis taps new president Akesis gets FDA clearance for radiosurgery system RT improves elderly brain cancer patient survival Akesis launches new rad therapy systems at ASTRO 2019 Is thermal ablation effective for treating NSCLC? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 18, 2021 Category: Radiology Source Type: news

Significant variation found in timing andselection of genetic tests for non--small-cell lung cancer
(Elsevier) Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however its use has complicated the diagnosis of non-small-cell lung cancer (NSCLC). In a new study inThe Journal of Molecular Diagnosis, published by Elsevier, investigators provide for the first time a complete overview of biomarker testing, spanning multiple treatment lines, in a single cohort of patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 15, 2021 Category: International Medicine & Public Health Source Type: news

AI reduces FDG dose on PET imaging
An artificial intelligence (AI) algorithm can process F-18 FDG PET exams acquire...Read more on AuntMinnie.comRelated Reading: FDG-PET/MRI offers option for pediatric Hodgkin lymphoma FDG-PET/CT shows COVID-19 vaccine uptake Radiomics, AI can guide NSCLC treatment decisions PET/CT guidance offers valuable approach to lung biopsies PET/MRI, CT predict pancreatic cancer treatment response (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 12, 2021 Category: Radiology Source Type: news

Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)
About 235,000 people in the US will be diagnosed with lung cancer in 2021, with non-small cell lung cancer (NSCLC) accounting for 84 percent of all lung cancers(1) ALK - anaplastic lymphoma kinase - is an important biomarker found in NSCLC, and targeted... Diagnostics, Oncology, FDA Roche Group, VENTANA ALK, LORBRENA, lorlatinib, NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 9, 2021 Category: Pharmaceuticals Source Type: news

Detecting hidden circulating tumor cells in non-small cell lung cancer patients
(Institute for Systems Biology) Non-Small Cell Lung Cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80 percent of all lung cancer cases. Despite the aggressive nature of NSCLC, circulating tumor cells that lead to metastases often go undetected in the blood compared to breast, prostate, colorectal, and other cancers.   Now, scientists have developed a novel method to better detect the circulating tumor cells that are a telltale sign of metastases. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 9, 2021 Category: International Medicine & Public Health Source Type: news

Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
This study did not meet its primary endpoint of overall survival in the PD-L1 high patient population. Subsequently, the FDA designated the IMvigor130 study as the PMR which will still continue until the final analysis. However, as the treatment landscape in prior-platinum (second-line) mUC has rapidly evolved with the emergence of new treatment options, Roche is voluntarily withdrawing this indication in recognition of the principles of the Accelerated Approval Program.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour c...
Source: Roche Media News - March 8, 2021 Category: Pharmaceuticals Source Type: news

Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
This study did not meet its primary endpoint of overall survival in the PD-L1 high patient population. Subsequently, the FDA designated the IMvigor130 study as the PMR which will still continue until the final analysis. However, as the treatment landscape in prior-platinum (second-line) mUC has rapidly evolved with the emergence of new treatment options, Roche is voluntarily withdrawing this indication in recognition of the principles of the Accelerated Approval Program.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour c...
Source: Roche Investor Update - March 8, 2021 Category: Pharmaceuticals Source Type: news

Dracen Announces Clinical Collaboration with Merck
Dracen will develop sirpiglenastat (DRP-104) in combination with KEYTRUDA® in selected patients with Non-Small Cell Lung Cancer(PRWeb March 08, 2021)Read the full story at https://www.prweb.com/releases/dracen_announces_clinical_collaboration_with_merck/prweb17775654.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 8, 2021 Category: Pharmaceuticals Source Type: news

FDA approves lorlatinib for metastatic ALK-positive NSCLC
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 4, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Biocon Biologics, Viatris Inc. get CHMP nod for Abevmy, a biosimilar to Avastin
Abevmy is abiosimilar to Roche's Avastin, prescribed for all indications including metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen, it said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 1, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Cemiplimab-rwlc for NSCLC With PD-L1 Expression FDA Approves Cemiplimab-rwlc for NSCLC With PD-L1 Expression
The FDA has approved cemiplimab-rwlc as monotherapy for first-line treatment of advanced non –small cell lung cancer (NSCLC) with PD-L1 expression of at least 50%.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 24, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Libtayo (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-Small Cell Lung Cancer with PD-L1 Expression of ≥50%
TARRYTOWN, N.Y. and PARIS, Feb. 22, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 22, 2021 Category: Drugs & Pharmacology Source Type: news

FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression
Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 22, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer
(University of Texas M. D. Anderson Cancer Center) The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 18, 2021 Category: Cancer & Oncology Source Type: news

The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of and#8805;50%
Libtayo was superior in extending overall survival compared to chemotherapy even with a high crossover rate Data are the basis for multiple ongoing regulatory submissions, including in the U.S. and European Union TARRYTOWN, N.Y. and PARIS, Feb. 12, 2... Biopharmaceuticals, Oncology Regeneron Pharmaceuticals, Sanofi, Libtayo, cemiplimab, NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 12, 2021 Category: Pharmaceuticals Source Type: news

Amivantamab Shows Promise in Challenging EGFR-Mutated NSCLC Amivantamab Shows Promise in Challenging EGFR-Mutated NSCLC
The novel drug appears to be effective for patients with EGFR-mutated NSCLC that has a hard-to-treat exon 20 insertion after disease progression with platinum-based chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 11, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Customized Chemotherapy Did Not Improve Survival in Early NSCLC Customized Chemotherapy Did Not Improve Survival in Early NSCLC
Tailoring adjuvant chemotherapy based on the expression of two molecular markers did not confer a survival advantage in patients with completely resected stage 2-3 NSCLC in a phase 3 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 10, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Combo Immunotherapy in NSCLC: Not These Two Drugs Combo Immunotherapy in NSCLC: Not These Two Drugs
Pembrolizumab monotherapy remains a standard of care, after trial results show that adding ipilimumab conveys no benefits but incurs greater toxicity.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 10, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

' Unprecedented' Long-term Survival After IO in Pretreated NSCLC'Unprecedented' Long-term Survival After IO in Pretreated NSCLC
For patients with non –small cell lung cancer (NSCLC) who experiecne disease progression with chemotherapy, immunotherapy (IO) offers an"unprecedented" chance of long-term survival, says an expert.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 9, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Sotorasib in NSCLC:'Historic Milestone' Reached Sotorasib in NSCLC:'Historic Milestone' Reached
The KRAS inhibitor sotorasib provides durable clinical benefit in heavily pretreated patients with non –small cell lung cancer (NSCLC) harboring KRAS p.G12C mutations, results of a phase 2 trial suggest.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 9, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Residential Segregation May Worsen NSCLC Outcomes for Black Patients
Blacks more likely to present at advanced stage, less likely to receive surgery, have higher mortality at higher residential segregation levels (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - February 5, 2021 Category: Respiratory Medicine Tags: Oncology, Pulmonology, Surgery, Conference News, Source Type: news

Residential Segregation May Worsen NSCLC Outcomes for Black Patients
FRIDAY, Feb. 5, 2021 -- Black patients are more likely to present with advanced non-small cell lung cancer (NSCLC) and are less likely to receive surgery at higher residential segregation levels, according to a study presented at the annual meeting... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 5, 2021 Category: Pharmaceuticals Source Type: news

FDA Grants MET Inhibitor Tepotinib Accelerated Approval for NSCLC FDA Grants MET Inhibitor Tepotinib Accelerated Approval for NSCLC
The US Food and Drug Administration has granted accelerated approval for tepotinib for the treatment of adults with metastatic non –small cell lung cancer harboring MET exon 14 skipping alterations.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 4, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Opdivo Study Offers Hope to Relapsed Mesothelioma Patients
A recent study out of the United Kingdom finds patients with relapsed malignant mesothelioma can be treated effectively with single-agent nivolumab, safely improving overall and progression-free survival. Nivolumab, also known by the brand name Opdivo, is an immunotherapy drug already being used successfully with non-small cell lung cancer. It is the first drug to show a significant survival advantage for relapsed mesothelioma in a phase III clinical trial, according to principal investigator Dr. Dean Fennell, medical oncologist at the University of Leicester in England. “This is very encouraging news,” Fennell...
Source: Asbestos and Mesothelioma News - February 4, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

MYLUNG Study Launches, Aiming to Advance Use of Precision Medicine for Metastatic Non-Small Cell Lung Cancer Patients
Unique, collaborative real-world research consortium will study up to 12,000 NSCLC patients in the community setting over five yearsMYLUNG to deepen understanding of barriers and address challenges to improve care for lung cancer patients, including those with targetable mutations (Source: McKesson News)
Source: McKesson News - February 4, 2021 Category: Information Technology Source Type: news

FDA Approves Tepmetko (tepotinib) as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations
ROCKLAND, Mass., Feb. 3, 2021 /PRNewswire/ -- EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that the US Food and Drug Administration (FDA) has approved Tepmetko® (tepotinib)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 3, 2021 Category: Drugs & Pharmacology Source Type: news

FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 3, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

' Astonishing' 4-Year Survival in NSCLC With Pembro+Chemo'Astonishing' 4-Year Survival in NSCLC With Pembro+Chemo
New data showing a doubling in survival with the combination versus chemo alone have been hailed as"very impressive", even"astonishing", by clinicians.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

How higher radiation stacks up when treating lung cancer
Two studies presented at the International Association for the Study of Lun...Read more on AuntMinnie.comRelated Reading: Radiomics, AI can guide NSCLC treatment decisions Radiomics can aid management of lung cancer patients PET shows promise for detecting NSCLC recurrence New treatments lead to drop in lung cancer deaths Radiomics can predict treatment outcome for NSCLC (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 1, 2021 Category: Radiology Source Type: news

Patients with lung cancer reduce smoking rate after enrollment in phase III clinical trial
(International Association for the Study of Lung Cancer) The first comprehensive, prospective study of smoking habits in patients with non-small cell lung cancer (NSCLC) who were enrolled in a phase III early-stage trial revealed that there was a high rate of smoking reduction and cessation following study entry, according to research published today in theJournal of Thoracic Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 1, 2021 Category: Cancer & Oncology Source Type: news

Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC
(International Association for the Study of Lung Cancer) Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration (TTD) in pain in chest, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. The research was presented today at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer Singapore. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 31, 2021 Category: Cancer & Oncology Source Type: news